Anti-CHRFAM7A monoclonal antibody
Pre-made anti-CHRFAM7A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to CHRFAM7A/CHRFAM7A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP0544-Ab-1/ GM-Tg-hg-IP0544-Ab-2 | Anti-Human CHRFAM7A monoclonal antibody | Human |
GM-Tg-rg-IP0544-Ab-1/ GM-Tg-rg-IP0544-Ab-2 | Anti-Rat CHRFAM7A monoclonal antibody | Rat |
GM-Tg-mg-IP0544-Ab-1/ GM-Tg-mg-IP0544-Ab-2 | Anti-Mouse CHRFAM7A monoclonal antibody | Mouse |
GM-Tg-cynog-IP0544-Ab-1/ GM-Tg-cynog-IP0544-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CHRFAM7A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP0544-Ab-1/ GM-Tg-felg-IP0544-Ab-2 | Anti-Feline CHRFAM7A monoclonal antibody | Feline |
GM-Tg-cang-IP0544-Ab-1/ GM-Tg-cang-IP0544-Ab-2 | Anti-Canine CHRFAM7A monoclonal antibody | Canine |
GM-Tg-bovg-IP0544-Ab-1/ GM-Tg-bovg-IP0544-Ab-2 | Anti-Bovine CHRFAM7A monoclonal antibody | Bovine |
GM-Tg-equg-IP0544-Ab-1/ GM-Tg-equg-IP0544-Ab-2 | Anti-Equine CHRFAM7A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP0544-Ab-1/ GM-Tg-hg-IP0544-Ab-2; GM-Tg-rg-IP0544-Ab-1/ GM-Tg-rg-IP0544-Ab-2; GM-Tg-mg-IP0544-Ab-1/ GM-Tg-mg-IP0544-Ab-2; GM-Tg-cynog-IP0544-Ab-1/ GM-Tg-cynog-IP0544-Ab-2; GM-Tg-felg-IP0544-Ab-1/ GM-Tg-felg-IP0544-Ab-2; GM-Tg-cang-IP0544-Ab-1/ GM-Tg-cang-IP0544-Ab-2; GM-Tg-bovg-IP0544-Ab-1/ GM-Tg-bovg-IP0544-Ab-2; GM-Tg-equg-IP0544-Ab-1/ GM-Tg-equg-IP0544-Ab-2 |
Products Name | Anti-CHRFAM7A monoclonal antibody |
Format | mab |
Target Name | CHRFAM7A |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-CHRFAM7A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP0544-Ag-1 | Recombinant multi-species CRFM7/ CHRFAM7A/ CHRNA7 protein |
Target information
Target ID | GM-IP0544 |
Target Name | CHRFAM7A |
Gene ID | 89832 |
Gene Symbol and Synonyms | CHRFAM7A,CHRNA7,CHRNA7-DR1,D-10,NACHRA7 |
Uniprot Accession | Q494W8 |
Uniprot Entry Name | CRFM7_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000166664 |
Target Classification | N/A |
The target: CHRFAM7A, gene name: CHRFAM7A, also named as CHRNA7, CHRNA7-DR1, D-10, NACHRA7. The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The family member CHRNA7, which is located on chromosome 15 in a region associated with several neuropsychiatric disorders, is partially duplicated and forms a hybrid with a novel gene from the family with sequence similarity 7 (FAM7A). Alternative splicing has been observed, and two variants exist, for this hybrid gene. The N-terminally truncated products predicted by the largest open reading frames for each variant would lack the majority of the neurotransmitter-gated ion-channel ligand binding domain but retain the transmembrane region that forms the ion channel. Although current evidence supports transcription of this hybrid gene, translation of the nicotinic acetylcholine receptor-like protein-encoding open reading frames has not been confirmed. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.